In patients with unresectable liver metastases, chemotherapy associated with antiangiogenic (anti-VEGF) or anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies obtains a median survival even exceeding 30 months, allowing a secondary resection in some cases with major tumor shrinkage [3,4,5,6]. The gene discussed is EGFR; the disease is neoplasm.